Diapharm has opened its branch in Shanghai in reaction to a surging demand for pharmaceutical consultancy services in China.

Diapharm helps pharmaceutical companies to obtain drug approval in Europe and assists them in quality assurance. “We will advise and assist Chinese companies as they make their way to Europe and also support European companies that purchase active ingredients or finished products from China and that may require assistance in auditing their suppliers,” Ralf Sibbing, general manager of Diapharm, explains.

Internationalisation of traditional Chinese medicine

Diapharm will assist Chinese pharmaceutical manufacturer Chengdu Huasun Group with registering their sanchi-tongshu capsules in Europe. Zhou Yunjin, president of Chengdu Huasun Group, and Ralf Sibbing, managing director of Diapharm, signed a corresponding cooperation agreement in Chengdu on 30 June 2014. The objective is to achieve EU approval for the medicinal product in several EU countries for the treatment of heart ailments. The product is based on active ingredients used in traditional Chinese medicine (TCM).

“Sanchi-tongshu capsules are also a pilot project for the modernisation and internationalisation of traditional Chinese medicine,” Zhou Menglin, vice director of Sichuan Science and Technology Department, emphasised at the signing. Huasun president Zhou Yunjin said: “With a share of more than 40 per cent, Europe is the largest market for traditional medicine.” The Huasun Group is one of the leading manufacturers of biopharmaceuticals and TCM products in China.

more about diapharm